Loading…
← CockpitCompetitor Analysis › 600993.SS Mayinglong Pharmaceutical Group Co., Ltd. Class AOpen in the cockpit ↗

Mayinglong Pharmaceutical Group Co., Ltd. Class A600993.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

China's best-known hemorrhoid-ointment brand, now also selling musk-based skincare and other OTC health products.

≈ A single-brand Chinese Preparation H makerMomentum leader 95
Mkt cap
$1.70B
US dollars, full cap
Free float
62%
of shares outstanding
$/day
$25.7M
20-day average traded
Fwd P/E
17.0×
forward earnings
ROIC−WACC
+15.8 pp
WACC 5.6%
Hurdle
-10 pp
Req g minus delivered
Next earnings
127 days
25 Mar 2027
Close · CNYCN¥25.97
1D-0.9%
1W+7.5%
1M+6.2%
3M+11.6%
6M+1.8%
YTD-7.2%
1Y-9.8%
ATR %2.5%
52w lowhigh13.9% off high

What Mayinglong Pharmaceutical does

China's best-known hemorrhoid-ointment brand, now also selling musk-based skincare and other OTC health products.

Depends on one product family: the musk hemorrhoid ointment and suppositories, sold mostly through pharmacy chains and online, dominate what the company earns. Skincare and other OTC health products, many using the same musk ingredient, are its route to broaden that base.

In one line: A single-brand Chinese Preparation H maker.

Products and services

  • Hemorrhoid ointment/suppository
  • Musk-based skincare
  • Other OTC products

Customers

  • Retail pharmacies
  • E-commerce consumers

Where it sits in the supply chain

  • Pharmaceuticals
  • OTC consumer health
  • Topical ointments and skincare

What could go right

  • Brand extension into new consumer categories
  • E-commerce sales growth

What could go wrong

  • Single-category brand dependence
  • OTC price competition

Moat: narrow (brand). Decades-old, near-household-name OTC brand with strong pharmacy shelf presence.

Headquarters: Wuhan, China · Employees: 2,544

Named competitors

Mayinglong Pharmaceutical at a glance

Size Mayinglong Pharmaceutical (600993.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.70B, the 1355th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥25.97 on 18 Nov 2026.

Performance Over six months the shares gained 1.8%, against -3.0% for the median peer and -20.0% for the China market (cap-weighted) — 10th highest of 20 in its peer set.

Growth Revenue grew 6.6% over the last twelve months (peer median +13.8%); the operating margin is 16.7% (peer median 12.0%).

Valuation It trades at 17.0× forward earnings against a peer median of 22.0× (4th cheapest of 16).

Price implies For today's price to make sense, revenue must grow about -3% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -10 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 15.8 points above its cost of capital (5.6% WACC).

Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).

Relative performance

9010021 May 202621 Aug 202618 Nov 2026600993.SS 105Peer median 96
Six months, rebased to 100: Mayinglong Pharmaceutical against the median of its 20 peers (local-currency closes).

Mayinglong Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥3.99BCN¥3.84BCN¥3.70BCN¥3.11BCN¥3.51B
Revenue growth—+4%+19%-11%—
Gross profitCN¥1.90BCN¥1.83BCN¥1.67BCN¥1.25BCN¥1.43B
EBITDAn/aCN¥745MCN¥675MCN¥471MCN¥577M
Net incomeCN¥595MCN¥581MCN¥528MCN¥443MCN¥479M
Free cash flowCN¥691MCN¥481MCN¥294MCN¥373MCN¥297M
Capital expenditureCN¥106MCN¥119MCN¥204MCN¥248MCN¥75.0M
Total debtCN¥246MCN¥252MCN¥398MCN¥380MCN¥801M

Quarterly statements and history in the cockpit →

Mayinglong Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%-20%0%+20%CAPLIPOINTINDGN300723FAEMAZE688166300357NATCOPHARM1681AGIO9989ASTRAZEN600664ETONANURAS3010473933002755600993.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Mayinglong Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%20×40×60×80×CAPLIPOINTINDGN300723FAE688166300357NATCOPHARM16819989600664ETONANURAS3010473933002755600993.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Mayinglong Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%200%CAPLIPOINTINDGN3007231681ASTRAZENETON301047600993.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Mayinglong Pharmaceutical is the large dot.

Mayinglong Pharmaceutical competitors and peer comparison

Head to head with its named competitors (600993.SS vs 000999.SZ vs 000538.SZ vs PFE)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Mayinglong Pharmaceutical 600993.SS$1.70B+2%+7%17%17.0×-3.5%
China Resources Sanjiu Medical & Pharmaceutical 000999.SZ$6.59B+6%+4%14%13.2×-6.2%
Yunnan Baiyao 000538.SZ$15.0B+11%+5%11%18.3×-0.2%
Pfizer PFE$160B+9%+1%26%9.9×-4.3%

How Mayinglong Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Mayinglong Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure600993.SSPeer medianRank in peer set
1-month return+6.2%-2.8%5th highest of 21
6-month return+1.8%-3.0%10th highest of 20
Distance from 52-week high-13.9%-36.7%5th highest of 21
Revenue growth (TTM)+6.6%+13.8%9th lowest of 20
Operating margin16.7%12.0%7th highest of 20
Forward P/E17.0×22.0×4th cheapest of 16
Growth the price implies (Req g, 7 yrs)-3.5%19.5%3rd least demanding of 17
Growth delivered (Del g)+6.8%+9.6%6th lowest of 17
Hurdle (Req g minus delivered)-10.2 pp+4.8 pp4th least demanding of 17
ROIC minus cost of capital+15.8 pp-2.7 pp4th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Mayinglong Pharmaceutical 600993.SSChina$1.70B+2%+7%17%17.0×-3.5%+6.8%
Caplin Point Laboratories CAPLIPOINT.NSIndia$1.70B+2%+17%31%21.4×24.3%+15.7%
Indegene INDGN.NSIndia$1.69B+28%+36%12%29.5×31.4%+29.4%
ApicHope Pharmaceutical 300723.SZChina$1.70B-36%-28%-50%22.0×11.3%-11.0%
Faes Farma FAE.MCSpain$1.71B+6%+32%14%17.4×3.7%+9.9%
Maze Therapeutics MAZEUnited States$1.71B+27%-100%-821%n/an/an/a
BrightGene Bio-Medical Technology 688166.SSChina$1.71B-57%+14%7%74.9×35.3%+9.2%
Zhejiang Wolwo Bio-Pharmaceutical 300357.SZChina$1.67B-12%+7%39%26.3×18.4%+10.8%
Braveheart Bio BRVEUnited States$1.67Bn/an/an/an/an/an/a
NATCO Pharma NATCOPHARM.NSIndia$1.73B-27%-30%17%19.1×20.5%+19.0%
Consun Pharmaceutical 1681.HKHong Kong$1.65B+8%+15%35%9.2×-14.9%+13.5%
Tonghua Golden-Horse Pharmaceutical Industry 000766.SZChina$1.62B-47%-18%9%n/a33.0%+0.9%
Agios Pharmaceuticals AGIOUnited States$1.78B+4%+214%-298%n/an/an/a
Shenzhen Hepalink Pharmaceutical 9989.HKHong Kong$1.78B-13%-1%8%8.7×-0.4%-0.2%
AstraZeneca Pharma India ASTRAZEN.NSIndia$1.62B-30%+30%10%n/a42.4%+23.0%
Harbin Pharmaceutical 600664.SSChina$1.78B+32%+2%5%19.7×-5.3%+8.2%
Eton Pharmaceuticals ETONUnited States$1.79B+226%+101%29%24.6×21.9%+359.6%
Anupam Rasayan India ANURAS.NSIndia$1.61B-3%+24%16%49.9×n/an/a
Sino Biological 301047.SZChina$1.60B+27%+20%17%51.6×31.1%-15.1%
United Laboratories International 3933.HKHong Kong$1.80B-20%-13%5%13.0×1.2%+7.8%
Beijing Aosaikang Pharmaceutical 002755.SZChina$1.60B-31%-13%12%57.4×12.8%-14.0%

Questions

Who are Mayinglong Pharmaceutical's main competitors?
Named competitors: China Resources Sanjiu (000999.SZ), Yunnan Baiyao (000538.SZ), Pfizer (Preparation H) (PFE). The cockpit's measured peer set (industry) also includes Caplin Point Laboratories (CAPLIPOINT.NS), Indegene (INDGN.NS), ApicHope Pharmaceutical (300723.SZ), Faes Farma (FAE.MC), Maze Therapeutics (MAZE), BrightGene Bio-Medical Technology (688166.SS).
Is Mayinglong Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 17.0× against a peer median of 22.0×, 4th cheapest of 16 in its peer set. For today's price to make sense, revenue must grow about -3% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -10 pp: the price already allows for a slowdown.
How has Mayinglong Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned +1.8% against -3.0% for the median peer; over one year -9.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.